ALNY
Alnylam Pharmaceuticals Inc
219.70$
-5.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -327.6% | -460.2% | -652.5% | -425.7% | -751.1% | -126.7% | -124.8% | -76.0% | -52.2% | 5.7% | -0.4% | 14.1% | |
| 23.6% | 46.4% | 32.1% | 14.9% | 8.6% | 24.7% | 15.1% | 10.6% | 8.2% | 5.3% | 2.5% | 1.5% | |
| 65.4% | 111.4% | 160.2% | 103.2% | 210.6% | 79.6% | 28.4% | 19.6% | 22.2% | 12.1% | 12.1% | 9.4% | |
| -13.0% | 113.8% | 153.1% | 108.6% | 248.7% | 91.8% | 31.8% | 26.5% | 29.7% | – | – | – | |
| -58.1% | 85.4% | 36.5% | -3.2% | 60.2% | 183.1% | -2.6% | -19.3% | -3.4% | 0.6% | -9.5% | -12.0% | |
| 17.7% | 31.5% | 136.9% | 115.9% | 169.4% | 63.8% | 14.3% | 9.0% | 6.9% | 3.4% | 1.5% | 1.6% | |
| -1,085.4% | -781.9% | 302.4% | -322.9% | 364.4% | -190.1% | -88.4% | -32.4% | 16.3% | -18.4% | -5.2% | 11.7% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| -31.6% | -0.9% | -1.3% | -0.3% | -4.6% | 388.3% | 60.9% | 29.2% | 25.0% | – | – | – | |
| 296.7% | 365.0% | 318.1% | -133.5% | -40.0% | -13.7% | 40.6% | 59.2% | 24.5% | 0.0% | 0.0% | -14.7% | |
| 1,456.6% | 1,499.3% | 377.1% | 1,251.1% | 87.4% | 374.6% | 201.9% | 147.7% | 41.0% | 9.4% | 13.1% | -8.2% | |
| 43.5% | 257.2% | 27.0% | 502.4% | -299.3% | 57.8% | -10.3% | 38.3% | 4.5% | -2.9% | 6.8% | 18.6% | |
| -345.3% | -491.7% | -789.4% | -541.6% | -920.5% | -190.5% | -139.1% | -85.0% | -59.1% | 2.3% | -1.9% | 12.5% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.